Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

Michelle Rosenzwajg, Guillaume Churlaud, Roberto Mallone, Adrien Six, Nicolas Dérian, Wahiba Chaara, Roberta Lorenzon, S. Alice Long, Jane H. Buckner, Georgia Afonso, Hang Phuong Pham, Agnès Hartemann, Aixin Yu, Alberto Pugliese, Thomas Malek, David Klatzmann

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Most autoimmune diseases (AID) are linked to an imbalance between autoreactive effector T cells (Teffs) and regulatory T cells (Tregs). While blocking Teffs with immunosuppression has long been the only therapeutic option, activating/expanding Tregs may achieve the same objective without the toxicity of immunosuppression. We showed that low-dose interleukin-2 (ld-IL-2) safely expands/activates Tregs in patients with AID, such HCV-induced vasculitis and Type 1 Diabetes (T1D). Here we analyzed the kinetics and dose-relationship of IL-2 effects on immune responses in T1D patients. Ld-IL-2 therapy induced a dose-dependent increase in CD4<sup>+</sup>Foxp3<sup>+</sup> and CD8<sup>+</sup>Foxp3<sup>+</sup> Treg numbers and proportions, the duration of which was markedly dose-dependent. Tregs expressed enhanced levels of activation markers, including CD25, GITR, CTLA-4 and basal pSTAT5, and retained a 20-fold higher sensitivity to IL-2 than Teff and NK cells. Plasma levels of regulatory cytokines were increased in a dose-dependent manner, while cytokines linked to Teff and Th17 inflammatory cells were mostly unchanged. Global transcriptome analyses showed a dose-dependent decrease in immune response signatures. At the highest dose, Teff responses against beta-cell antigens were suppressed in all 4 patients tested. These results inform of broader changes induced by ld-IL-2 beyond direct effects on Tregs, and relevant for further development of ld-IL-2 for therapy and prevention of T1D, and other autoimmune and inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)48-58
Number of pages11
JournalJournal of Autoimmunity
Volume58
DOIs
StatePublished - Apr 1 2015

Fingerprint

Regulatory T-Lymphocytes
Type 1 Diabetes Mellitus
Interleukin-2
Eragrostis
Autoimmune Diseases
Immunosuppression
Cytokines
Th17 Cells
Gene Expression Profiling
Vasculitis
Natural Killer Cells
Therapeutics
T-Lymphocytes
Antigens

Keywords

  • Immunopathology
  • Immunotherapy
  • Inflammation
  • Pharmacokinetics
  • Tolerance

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Rosenzwajg, M., Churlaud, G., Mallone, R., Six, A., Dérian, N., Chaara, W., ... Klatzmann, D. (2015). Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. Journal of Autoimmunity, 58, 48-58. https://doi.org/10.1016/j.jaut.2015.01.001

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. / Rosenzwajg, Michelle; Churlaud, Guillaume; Mallone, Roberto; Six, Adrien; Dérian, Nicolas; Chaara, Wahiba; Lorenzon, Roberta; Long, S. Alice; Buckner, Jane H.; Afonso, Georgia; Pham, Hang Phuong; Hartemann, Agnès; Yu, Aixin; Pugliese, Alberto; Malek, Thomas; Klatzmann, David.

In: Journal of Autoimmunity, Vol. 58, 01.04.2015, p. 48-58.

Research output: Contribution to journalArticle

Rosenzwajg, M, Churlaud, G, Mallone, R, Six, A, Dérian, N, Chaara, W, Lorenzon, R, Long, SA, Buckner, JH, Afonso, G, Pham, HP, Hartemann, A, Yu, A, Pugliese, A, Malek, T & Klatzmann, D 2015, 'Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients', Journal of Autoimmunity, vol. 58, pp. 48-58. https://doi.org/10.1016/j.jaut.2015.01.001
Rosenzwajg, Michelle ; Churlaud, Guillaume ; Mallone, Roberto ; Six, Adrien ; Dérian, Nicolas ; Chaara, Wahiba ; Lorenzon, Roberta ; Long, S. Alice ; Buckner, Jane H. ; Afonso, Georgia ; Pham, Hang Phuong ; Hartemann, Agnès ; Yu, Aixin ; Pugliese, Alberto ; Malek, Thomas ; Klatzmann, David. / Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. In: Journal of Autoimmunity. 2015 ; Vol. 58. pp. 48-58.
@article{3351852cce664df7be41afa5835b8851,
title = "Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients",
abstract = "Most autoimmune diseases (AID) are linked to an imbalance between autoreactive effector T cells (Teffs) and regulatory T cells (Tregs). While blocking Teffs with immunosuppression has long been the only therapeutic option, activating/expanding Tregs may achieve the same objective without the toxicity of immunosuppression. We showed that low-dose interleukin-2 (ld-IL-2) safely expands/activates Tregs in patients with AID, such HCV-induced vasculitis and Type 1 Diabetes (T1D). Here we analyzed the kinetics and dose-relationship of IL-2 effects on immune responses in T1D patients. Ld-IL-2 therapy induced a dose-dependent increase in CD4+Foxp3+ and CD8+Foxp3+ Treg numbers and proportions, the duration of which was markedly dose-dependent. Tregs expressed enhanced levels of activation markers, including CD25, GITR, CTLA-4 and basal pSTAT5, and retained a 20-fold higher sensitivity to IL-2 than Teff and NK cells. Plasma levels of regulatory cytokines were increased in a dose-dependent manner, while cytokines linked to Teff and Th17 inflammatory cells were mostly unchanged. Global transcriptome analyses showed a dose-dependent decrease in immune response signatures. At the highest dose, Teff responses against beta-cell antigens were suppressed in all 4 patients tested. These results inform of broader changes induced by ld-IL-2 beyond direct effects on Tregs, and relevant for further development of ld-IL-2 for therapy and prevention of T1D, and other autoimmune and inflammatory diseases.",
keywords = "Immunopathology, Immunotherapy, Inflammation, Pharmacokinetics, Tolerance",
author = "Michelle Rosenzwajg and Guillaume Churlaud and Roberto Mallone and Adrien Six and Nicolas D{\'e}rian and Wahiba Chaara and Roberta Lorenzon and Long, {S. Alice} and Buckner, {Jane H.} and Georgia Afonso and Pham, {Hang Phuong} and Agn{\`e}s Hartemann and Aixin Yu and Alberto Pugliese and Thomas Malek and David Klatzmann",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.jaut.2015.01.001",
language = "English (US)",
volume = "58",
pages = "48--58",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

AU - Rosenzwajg, Michelle

AU - Churlaud, Guillaume

AU - Mallone, Roberto

AU - Six, Adrien

AU - Dérian, Nicolas

AU - Chaara, Wahiba

AU - Lorenzon, Roberta

AU - Long, S. Alice

AU - Buckner, Jane H.

AU - Afonso, Georgia

AU - Pham, Hang Phuong

AU - Hartemann, Agnès

AU - Yu, Aixin

AU - Pugliese, Alberto

AU - Malek, Thomas

AU - Klatzmann, David

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Most autoimmune diseases (AID) are linked to an imbalance between autoreactive effector T cells (Teffs) and regulatory T cells (Tregs). While blocking Teffs with immunosuppression has long been the only therapeutic option, activating/expanding Tregs may achieve the same objective without the toxicity of immunosuppression. We showed that low-dose interleukin-2 (ld-IL-2) safely expands/activates Tregs in patients with AID, such HCV-induced vasculitis and Type 1 Diabetes (T1D). Here we analyzed the kinetics and dose-relationship of IL-2 effects on immune responses in T1D patients. Ld-IL-2 therapy induced a dose-dependent increase in CD4+Foxp3+ and CD8+Foxp3+ Treg numbers and proportions, the duration of which was markedly dose-dependent. Tregs expressed enhanced levels of activation markers, including CD25, GITR, CTLA-4 and basal pSTAT5, and retained a 20-fold higher sensitivity to IL-2 than Teff and NK cells. Plasma levels of regulatory cytokines were increased in a dose-dependent manner, while cytokines linked to Teff and Th17 inflammatory cells were mostly unchanged. Global transcriptome analyses showed a dose-dependent decrease in immune response signatures. At the highest dose, Teff responses against beta-cell antigens were suppressed in all 4 patients tested. These results inform of broader changes induced by ld-IL-2 beyond direct effects on Tregs, and relevant for further development of ld-IL-2 for therapy and prevention of T1D, and other autoimmune and inflammatory diseases.

AB - Most autoimmune diseases (AID) are linked to an imbalance between autoreactive effector T cells (Teffs) and regulatory T cells (Tregs). While blocking Teffs with immunosuppression has long been the only therapeutic option, activating/expanding Tregs may achieve the same objective without the toxicity of immunosuppression. We showed that low-dose interleukin-2 (ld-IL-2) safely expands/activates Tregs in patients with AID, such HCV-induced vasculitis and Type 1 Diabetes (T1D). Here we analyzed the kinetics and dose-relationship of IL-2 effects on immune responses in T1D patients. Ld-IL-2 therapy induced a dose-dependent increase in CD4+Foxp3+ and CD8+Foxp3+ Treg numbers and proportions, the duration of which was markedly dose-dependent. Tregs expressed enhanced levels of activation markers, including CD25, GITR, CTLA-4 and basal pSTAT5, and retained a 20-fold higher sensitivity to IL-2 than Teff and NK cells. Plasma levels of regulatory cytokines were increased in a dose-dependent manner, while cytokines linked to Teff and Th17 inflammatory cells were mostly unchanged. Global transcriptome analyses showed a dose-dependent decrease in immune response signatures. At the highest dose, Teff responses against beta-cell antigens were suppressed in all 4 patients tested. These results inform of broader changes induced by ld-IL-2 beyond direct effects on Tregs, and relevant for further development of ld-IL-2 for therapy and prevention of T1D, and other autoimmune and inflammatory diseases.

KW - Immunopathology

KW - Immunotherapy

KW - Inflammation

KW - Pharmacokinetics

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=84928589620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928589620&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2015.01.001

DO - 10.1016/j.jaut.2015.01.001

M3 - Article

VL - 58

SP - 48

EP - 58

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

ER -